OTCM
GUBRF
Market cap732mUSD
May 06, Last price
60.15USD
Name
Gubra A/S
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Related entities
Subsidiaries (2)
Gubra Alpha ApS
Gubra Beta ApS
Key people
Henrik Blou
Chief Executive Officer · since 2016
Independent Deputy Chairman of the Board · since 2022
Jacob Jelsing
Co-Founder, Director · since 2025
Kristian Borbos
Chief Financial Officer · since 2022
Niels Vrang
Co-Founder, Director · since 2025
Astrid Haug
Independent Board Member
Monika Lessl
Independent Board Member
Claudia Mitchell
Independent Board Member · since 2025
Arndt Schottelius
Independent Board Member · since 2022
Headquarters & legal address
Hørsholm Kongevej 11 B
Hørsholm, 84 2970
DK
Hørsholm, 84 2970
DK
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT |